WAIKOLOA, Hawaii — Visual acuity letter score and central subfield thickness both improved in eyes treated with aflibercept after a poor response to bevacizumab, Michael S. Ip, MD, told colleagues at Retina 2019.
In a secondary analysis of the SCORE2 trial, poor responders at month 6 were switched from either aflibercept or bevacizumab to a different regimen to determine whether the switch would improve visual acuity or central subfield thickness at month 12.
“Notably, none of these eyes that have been deemed poor responders at month 6 ever catch up (Read more...)
Uncategorized